Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Algorithmic Computation of Combined LT4 Plus LT3 Replacement Therapies for Primary Hypothyroid Patients Individualized by Sex, Height, and Weight.

Created on 18 Nov 2026

Authors

Katarina Reid, Kasra Navabi, Rushil Shah, Joseph DiStefano

Published in

Thyroid : official journal of the American Thyroid Association. Pages 10507256261502926. Nov 18, 2026. Epub Nov 18, 2026.

Abstract

Levothyroxine (LT4) monotherapy fails to fully normalize thyroid hormone levels or relieve symptoms in 10-20% of hypothyroid patients, prompting interest in combination therapy with added liothyronine (LT3). Existing dosing guidance is largely qualitative. Using the p-THYROSIM mechanistic model-previously fitted and validated against data from 655 patients-we developed computational algorithms from ∼400 simulations to generate individualized residual thyroid function (RTF) values and combination LT4/LT3 dosing recommendations based on a patient's sex, height (H), weight (W), and measured hormone values [TSH, free thyroxine (fT4), and free triiodothyronine (fT3) or total T3 (TT3)]. We implemented these in a user-friendly clinical software package as an app called LT43DOSING.
Simulated temporal plots of fT4, fT3, and TSH for combined dosages in available pill sizes are computed and reported as outputs of LT43DOSING, along with RTFs, separately for both sexes, with body mass indexes (BMIs) ranging from ∼15 to 40. Computed RTFs and dosages are based on patient H, W, and serum hormone concentrations provided as input data. Our findings show that both W and H affect dosing in a nonlinear manner, especially at BMI extremes, whereas sex made little difference. Only combination therapy was able to normalize fT3 levels.
In simulated identical BMI patients, different H and W combinations produced markedly different RTF values, leading to more accurate dosing predictions based on body size. Simulated combination therapy normalized fT3 levels whereas monotherapy did not, particularly for overtly hypothyroid patients.

PMID:
43049475
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement